4JQV | HLA-B*18:01 in complex with Epstein-Barr virus BZLF1-derived peptide (residues 173-180) | date | 2013-03-20 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
authors | Theodossis, A., Welland, A., Gras, S., Rossjohn, J. | ||||||||||||||
compound | source | ||||||||||||||
symmetry |
| ||||||||||||||
crystal cell |
| ||||||||||||||
method | X-Ray Diffraction | resolution | 1.50 | ||||||||||||
ligand | ACT | enzyme |
| ||||||||||||
Gene Ontology |
| ||||||||||||||
Primary reference | HLA Peptide Length Preferences Control CD8+ T Cell Responses., Rist MJ, Theodossis A, Croft NP, Neller MA, Welland A, Chen Z, Sullivan LC, Burrows JM, Miles JJ, Brennan RM, Gras S, Khanna R, Brooks AG, McCluskey J, Purcell AW, Rossjohn J, Burrows SR, J Immunol. 2013 Jun 7. PMID:23749632 |
Data retrieval |
View 4JQV in 3D |
Visual 3D analysis of 4JQV |
Structure-derived information |
Sequence-derived information |
Other resources with information on 4JQV |
OCA© by Jaime Prilusky, 1996-2014,2022 Bioinformatics Unit Weizmann Institute of Science |